Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors

  title={Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors},
  author={Zbigniew Dutkiewicz and Renata Mikstacka},
  journal={Bioinorganic Chemistry and Applications},
Cytochromes P450 are a class of metalloproteins which are responsible for electron transfer in a wide spectrum of reactions including metabolic biotransformation of endogenous and exogenous substrates. The superfamily of cytochromes P450 consists of families and subfamilies which are characterized by a specific structure and substrate specificity. Cytochromes P450 family 1 (CYP1s) play a distinctive role in the metabolism of drugs and chemical procarcinogens. In recent decades, these… 

Figures and Tables from this paper

New Perspectives of CYP1B1 Inhibitors in the Light of Molecular Studies

Human cytochrome P450 1B1 (CYP1B1) is an extrahepatic heme-containing monooxygenase. CYP1B1 contributes to the oxidative metabolism of xenobiotics, drugs, and endogenous substrates like melatonin,

In Silico Design and SAR Study of Dibenzyl Trisulfide Analogues for Improved CYP1A1 Inhibition

Novel DTS analogues are designed, aimed at improving not only inhibitory activity, but also specificity toward CYP1A1 enzymes, and the most promising DTS analogue obeys Lipinski's rule of five.

Analysis of the Molecular Interactions between Cytochromes P450 3A4 and 1A2 and Aflatoxins: A Docking Study

The charge transfer values showed that there is oxidative damage inside the active site and that the HEM group is responsible for the main charge transferences.

Application of Various Molecular Modelling Methods in the Study of Estrogens and Xenoestrogens

In this review, applications of various molecular modelling methods in the study of estrogens and xenoestrogens are summarized. Selected biomolecules that are the most commonly chosen as molecular

The Multifarious Link between Cytochrome P450s and Cancer

The purposes of this review are to shed light on the current state of knowledge about the cancer molecular mechanism involving P450s and to summarize the link between the cancer effects and the participation of P 450s.

Inhibition of human CYP1 enzymes by a classical inhibitor α‐naphthoflavone and a novel inhibitor N‐(3, 5‐dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study

DCPCC is a candidate structure to modulate CYP1A2‐mediated metabolism of procarcinogens and anticancer drugs and is concluded to be a more selective inhibitor for CYP 1A2 than ANF.

In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants

In this in silico study several compounds with herbal origin suggested to have antidepressant activity were analyzed on their CYP2D6 wild-type and CYP1D6*53 inhibition potential using molecular docking to avoid toxicity issues.

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

This review has endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many Chemotherapeutic regimens.

Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B1.

A cell-based high-throughput high-content imaging assay was developed that enabled the team to test natural products and synthetic polyarene molecules that have undergone oxidative functionalization for protection of monolayers and spheroids composed of HepG2 liver cells against AfB1.



Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design

A homology model of CYP1A1 from Homo sapiens is developed on the basis of template crystal structure of human microsomal P450 1a2 in complex with inhibitor, which should prove useful in the design and development of potential novel anticancer agents.

Inhibition of cytochrome p450 enzymes by quinones and anthraquinones.

In silico docking studies and quantitative structure-activity relationship analysis of a number of in-house cytochrome P450 inhibitors have revealed important structural characteristics that are

Molecular Modeling of Cytochrome P450 1A1: Enzyme-Substrate Interactions and Substrate Binding Affinities

The analysis of enzyme-substrate interactions indicated that hydrophobic interactions are mainly responsible for binding of these substrates in the active site of the model, which is consistent with higher activity of 1A1 towards the former substrate.

Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism*

CYP1A1 has a planar active site that restricts ligand orientations, and Comparisons with previously determined structures of the related cytochrome P450 1A2 and 1B1 enzymes reveal distinct features among the active sites that may underlie the functional variability of these enzymes.

Identification of CYP1A2 Ligands by Structure-Based and Ligand-Based Virtual Screening

The applied virtual screening methods are useful for considering CYP1A2 inhibition, either to identify inhibitors of CYP 1A2, e.g. for cancer therapy, or to identify undesirable inhibitory effects of the enzyme.

A theoretical study on the mechanism of a superficial mutation inhibiting the enzymatic activity of CYP1A2

A detailed mechanism of how F186 regulates the functions of CYP1A2 was proposed, and it may shed light on the diverse effects of SNPs and the personalized drug design.

Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands

It was found that while docking can be used successfully to address the first two questions, it seems to be more difficult to perform the classification of individual compounds into active and inactive compounds.

In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1.

The results suggest that maximizing the pi-pi interactions with phenylalanine residues in the binding pocket and optimum proximity of the acetylene moiety to the heme Fe will provide for a substantial increase in the potency of the polyaromatic hydrocarbon mechanism-based inhibitors.